|
Press Releases |
|
|
|
Thursday, July 27, 2017 |
|
U.S. FDA Approves Additional Use of Antiepileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures |
Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. received approval from the U.S. FDA for a supplemental New Drug Application (sNDA) for Eisai's antiepileptic drug (AED) Fycompa (perampanel) as monotherapy use for the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 12 years of age and older. more info >> |
|
Wednesday, July 26, 2017 |
|
Eisai Submits Simultaneous Applications in The United States and Europe for Lenvatinib in Hepatocellular Carcinoma |
Eisai Co., Ltd. announced that it has submitted applications to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its in-house discovered and developed anticancer agent lenvatinib mesylate (lenvatinib) for the treatment of hepatocellular carcinoma (HCC). more info >> |
|
Tuesday, July 4, 2017 |
|
Wellness Open Living Labs. LLC, Co-Founded by Eisai and Osaka City University Conclude Basic Collaboration Agreement Aimed at Solving Health Problems |
Eisai Co., Ltd. announced today that Wellness Open Living Labs. LLC, co-founded by Eisai, and Osaka City University have concluded a basic collaboration agreement aimed at solving health science-related problems, such as dementia, and extending healthy life expectancy. more info >> |
|
Wednesday, June 28, 2017 |
|
Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment |
Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 16th consecutive year since its initial inclusion in 2002. more info >> |
|
Tuesday, June 27, 2017 |
|
Eisai Temporarily Withdraws New Drug Application for Anticancer Agent Halaven in China |
Eisai Co., Ltd. announced today that, in alignment with Chinese regulations, it has temporarily withdrawn its new drug application for anticancer agent eribulin mesylate (Brand name: Halaven) in China in order to submit additional documentation. more info >> |
|
Friday, June 23, 2017 |
|
Eisai Submits Application for Additional Indication of Anticancer Agent Lenvima for Hepatocellular Carcinoma in Japan |
Eisai Co., Ltd. announced today that it has submitted an application for an additional indication of its in-house discovered and developed anticancer agent Lenvima (generic name: lenvatinib mesylate) for the treatment of hepatocellular carcinoma (HCC) in Japan, the first in the world. more info >> |
|
Cardiovascular Outcomes Trial of Anti-Obesity Agent Lorcaserin to Continue Based on Recommendation of Independent Data Monitoring Committee After Completion of Interim Safety Analysis |
Eisai Co., Ltd. has announced that it has received a recommendation from an independent Data Monitoring Committee to continue the ongoing Cardiovascular Outcomes Trial of lorcaserin hydrochloride after the completion of a pre-specified interim safety analysis, evaluating the incidence of Major Adverse Cardiovascular Events (MACE), defined as cardiovascular death, myocardial infarction or stroke. more info >> |
|
Thursday, June 8, 2017 |
|
Launch of Pain Treatment Lyrica OD Tablet Formulation in Japan |
Pfizer Japan Inc. and Eisai Co., Ltd. have announced that Lyrica OD Tablets 25mg, 75mg, 150mg (OD tablet: orally disintegrating tablet), a new formulation following pain treatment Lyrica Capsules (pregabalin). more info >> |
|
Monday, June 5, 2017 |
|
Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-Line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd ASCO Annual Meeting |
Eisai Co., Ltd. announced today that the results of a Phase III trial (Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate against the comparator sorafenib as first-line treatment for unresectable hepatocellular carcinoma, will be orally presented during the 53rd Annual Meeting of ASCO. more info >> |
|
Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab |
Eisai Co., Ltd. announced the first results for metastatic endometrial carcinoma obtained from a Phase Ib/II study (Study 111) of its in-house developed multi-kinase inhibitor lenvatinib mesylate in combination with the MSD anti-PD-1 antibody pembrolizumab (brand name: KEYTRUDA), during a presentation at the 53rd Annual Meeting of ASCO. more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
GLOBE LIFE (GL): Kaplan Fox & Kilsheimer LLP Investigates GLOBE LIFE and Encourages Investors to Contact the Firm
Apr 19, 2024 08:00 HKT/SGT
|
|
|
e& life joins Dubai FinTech Summit as a Powered By sponsor
Apr 18, 2024 20:56 HKT/SGT
|
|
|
DC Healthcare Rides the Wave of Success with New Openings at Publika and Bukit Indah
Apr 18, 2024 19:33 HKT/SGT
|
|
|
Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST
|
|
|
Crown Digital Spearheads the Future of AI in F&B with Ella the Robobarista at AIM Global
Apr 18, 2024 16:00 HKT/SGT
|
|
|
Microex Launches Web3.0 Financial Trading Solution - Pioneering Innovation in Financial Technology
Apr 18, 2024 14:00 HKT/SGT
|
|
|
Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST
|
|
|
Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan
Apr 18, 2024 11:14 JST
|
|
|
The Executive Centre Announces Record Revenue in FY2023 Annual Results
Apr 18, 2024 10:00 HKT/SGT
|
|
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Apr 18, 2024 10:53 JST
|
|
|
All-New Triton Confirmed as First Double-Cab Pickup Truck to Achieve 2024 Five-Star ANCAP Safety Rating
Apr 18, 2024 9:22 JST
|
|
|
The Rapidly Evolving Real Estate Landscape: Redefine Real Estate Summit Connects Key Players in South East Asia
Apr 18, 2024 08:11 HKT/SGT
|
|
|
Prestigious titles for top developers at the 14th PropertyGuru Asia Property Awards (Singapore)
Apr 18, 2024 08:00 HKT/SGT
|
|
|
Eesee Implements Blockpass for Compliance in Digital Assets Marketplace
Apr 18, 2024 07:00 HKT/SGT
|
|
|
A new spin on materials analysis
Apr 17, 2024 22:00 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|